This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study
by Zacks Equity Research
Denali announces encouraging additional longer-term data from the phase I/II Hunter Syndrome study of its investigational therapy, tividenofusp alfa.
BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook
by Zacks Equity Research
BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 is below expectations.
LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of Estimates
by Zacks Equity Research
Eli Lilly beats fourth-quarter estimates for earnings and sales. Mounjaro and Zepbound sales miss estimates.
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study
by Zacks Equity Research
Ultragenyx announces new safety and efficacy data from its pivotal study of its investigational candidate, UX111, for patients with Sanfilippo syndrome type A.
GHRS Stock Rallies 55% in a Week: Here's What You Should Know
by Zacks Equity Research
GH Research stock soars 55% in a week after the company meets the primary goal in a mid-stage depression study of its lead candidate, GH001.
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?
by Zacks Equity Research
NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors already owning the stock can stay invested.
Are Medical Stocks Lagging Guardant Health (GH) This Year?
by Zacks Equity Research
Here is how Guardant Health (GH) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up
by Zacks Equity Research
Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes and Obesity care products.
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales
by Zacks Equity Research
PFE beats fourth-quarter estimates for earnings and sales. It maintains 2025 guidance.
PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS
by Zacks Equity Research
Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS with statistical significance.
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
by Zacks Equity Research
The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma and Breyanzi for relapsed or refractory follicular lymphoma.
Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings?
by Zacks Equity Research
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.
Bet on These 4 Top-Performing Liquid Stocks for Solid Gains
by Vaishali Doshi
Investors can boost returns by adding these top-ranked liquid stocks, Alnylam Pharmaceuticals, Frontdoor, EverQuote and Sezzle, to their portfolios.
Novartis Posts Q4 Earnings and Sales Beat, Shares Gain
by Zacks Equity Research
NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the company???s key drugs, it provides an encouraging outlook for 2025.
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
by Zacks Equity Research
CMPX stock more than doubles following updates regarding the pipeline development programs and current cash position by the company.
CMRX Stock Skyrockets in 3 Months: Here's What You Should Know
by Zacks Equity Research
Chimerix stock surges 324% in three months following NDA submission for high-grade glioma drug, dordaviprone, for accelerated approval in the United States.
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQJ
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQJ
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQJ
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQJ
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQJ
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQJ
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQJ
FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication
by Zacks Equity Research
The FDA approves AstraZeneca's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer in the United States.